Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment

An Open-Label, Clinical Pharmacology Study to Evaluate the Safety and PK of MRA in Patients With RA With Renal Impairment

This is an open-label, clinical pharmacology study to evaluate the safety and PK of MRA in patients with RA with Renal Impairment.

Inclusion criteria

• Patients who are diagnosed with RA according to the 1987 ACR (American College of Rheumatology) classification criteria
• Patients with RA at least 6 months prior to enrollment
• Patients with a creatinine clearance not less than 10 mL/min but no higher than 80 mL/min

Exclusion criteria

• Patients with Class IV Steinbrocker functional impairment at enrollment
• Patients who are undergoing dialysis
• Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept, and have been receiving treatment with leflunomide, within 12 weeks before treatment with the investigational product